Biomarin awaits crucial approvals and flat growth in 2021

2021 could turn out to be an important year for Biomarin, which expects to get a growth hormone against dwarfism approved on the one hand, while battling health authorities in the US and the EU on the other, as the firm attempts to get approvals for its gene therapy against hemophilia.
Photo: Manuel Balce Ceneta/AP/Ritzau Scanpix
Photo: Manuel Balce Ceneta/AP/Ritzau Scanpix
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN

In 2020, Biomarin's revenue has increased from USD 1.7bn to USD 1.9bn, which is the highest revenue in the history of the still-growing US company.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Foto: Mike Blake/Reuters/Ritzau Scanpix

    Gilead Sciences CMO to leave early 2025

    For subscribers

    Further reading